DYRK1A and acute myeloid leukemia: Interestingly, dual treatment with DYRK1A inhibitors and venetoclax synergize to increase cell death in several AML cell lines, while DYRK1A/CLK inhibition has also been proposed as a method to overcome venetoclax resistance in AML [90,91].